Results 101 to 110 of about 768 (176)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. [PDF]

Pharmacoecon Open, 2023
Martins P, Vandewalle B, Félix J, Capela CM, Cerqueira JJ, Salgado AV, Ferreira DG, Monteiro I.   +7 more
europepmc   +1 more source

Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review. [PDF]

Front Neurosci
Tauro C, Awada Z, Malhotra R, Harel A.
europepmc   +1 more source

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment. [PDF]

Curr Neuropharmacol
Margoni M, Battistini L, Centonze D, Furlan R, Gasperini C, Filippi M.   +5 more
europepmc   +1 more source

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. [PDF]

Eur J Neurol, 2022
Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, Kubala Havrdová E, Grand'Maison F, Prat A, Girard M, Hupperts R, Onofrj M, Lugaresi A, Taylor B, MSBase Study Group, Giovannoni G, Kappos L, Hauser SL, Montalban X, Craveiro L, Freitas R, Model F, Overell J, Muros-Le Rouzic E, Sauter A, Wang Q, Wormser D, Wolinsky JS.   +27 more
europepmc   +1 more source

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. [PDF]

Ther Adv Neurol Disord
Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A.   +14 more
europepmc   +1 more source

Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial. [PDF]

Mult Scler J Exp Transl Clin
Abbasi Kasbi N, Rezaei A, Montazeri R, Nikkhah Bahrami S, Rezaeimanesh N, Arab Bafrani M, Ghane Ezabadi S, Kohandel K, Khodaie F, Jahani S, Naser Moghadasi A, Azimi Saeen A, Navardi S, Heidari H, Ebadi Z, Sahraian MA.   +15 more
europepmc   +1 more source

Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. [PDF]

Neurotherapeutics, 2022
Havla J, Hohlfeld R.
europepmc   +1 more source

Oratorio & musique sacrée

CastrAlter, 2023
openaire   +2 more sources

Machine learning-based prediction of disease progression in primary progressive multiple sclerosis. [PDF]

Brain Commun
Gurevich M, Zilkha-Falb R, Sherman J, Usdin M, Raposo C, Craveiro L, Sonis P, Magalashvili D, Menascu S, Dolev M, Achiron A.   +10 more
europepmc   +1 more source

Ocrelizumab: A Review in Multiple Sclerosis. [PDF]

Drugs, 2022
Lamb YN.
europepmc   +1 more source